Payment overview · 2025
General Payments
$1,185.51
53 reported records · 16 companies
Healthcare provider profile · identity verified
Liss Speziale, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · CLIFTON, NJ · NPI 1992239487
Verified facts
What the public records show
CMS Open Payments records show Liss Speziale, NP received $1,185.51 in general payments during 2025 across 53 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 16.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $194.78 | 16.4% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $193.33 | 16.3% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $184.41 | 15.6% | 12 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $148.42 | 12.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.98 | 10.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $87.19 | 7.3% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $61.42 | 5.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $57.77 | 4.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.63 | 1.7% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $17.02 | 1.4% | 1 | 2025 |
| Metacel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.71 | 1.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.25 | 1.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.11 | 1.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.91 | 1.3% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $15.91 | 1.3% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $15.67 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,185.51 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $210.89 | 6 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $162.38 | 11 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $148.42 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $135.70 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $135.70 | 10 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $87.19 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $65.50 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $61.42 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $57.63 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.37 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $28.40 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| OZOBAX Normalized: ozobax |
Drug | Metacel Pharmaceuticals LLC | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 20 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 27 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 58 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
58 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 290 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 214 | 126 |
| Metformin Hcl | Metformin Hcl | 213 | 103 |
| Omeprazole | Omeprazole | 175 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 127 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 125 | 66 |
| Losartan Potassium | Losartan Potassium | 116 | 61 |
| Baclofen | Baclofen | 113 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 111 | 54 |
| Azithromycin | Azithromycin | 108 | 93 |
| Lisinopril | Lisinopril | 104 | 47 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 97 | 71 |
| Diclofenac Sodium | Diclofenac Sodium | 94 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 51 |
| Gabapentin | Gabapentin | 87 | 47 |
| Ibuprofen | Ibuprofen | 78 | 59 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 76 | 64 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 17 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 74 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 22 |
| Glipizide Er | Glipizide | 68 | 36 |
| Meclizine Hcl | Meclizine Hcl | 67 | 50 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 38 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 64 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 54 |
| Alendronate Sodium | Alendronate Sodium | 60 | 24 |
| Linzess | Linaclotide | 58 | 26 |
| Montelukast Sodium | Montelukast Sodium | 54 | 25 |
| Furosemide | Furosemide | 50 | 31 |
| Simvastatin | Simvastatin | 47 | 22 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 46 | 20 |
| Famotidine | Famotidine | 45 | 23 |
| Mirtazapine | Mirtazapine | 40 | 16 |
| Carvedilol | Carvedilol | 39 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 15 |
| Lorazepam | Lorazepam | 39 | suppressed |
| Alprazolam | Alprazolam | 37 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 36 | 25 |
| Glipizide | Glipizide | 35 | 17 |
| Meloxicam | Meloxicam | 35 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | 18 |
| Valsartan | Valsartan | 31 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | 20 |
| Methylprednisolone | Methylprednisolone | 29 | 28 |
| Atenolol | Atenolol | 28 | 15 |
| Enalapril Maleate | Enalapril Maleate | 27 | 15 |
| Jardiance | Empagliflozin | 27 | 12 |
| Megestrol Acetate | Megestrol Acetate | 27 | 16 |
| Donepezil Hcl | Donepezil Hcl | 25 | 16 |
| Memantine Hcl | Memantine Hcl | 25 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | 11 |
| Trazodone Hcl | Trazodone Hcl | 25 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 19 |
| Naproxen | Naproxen | 24 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | 15 |
| Januvia | Sitagliptin Phosphate | 22 | 11 |
| Cephalexin | Cephalexin | 21 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 17 |
| Farxiga | Dapagliflozin Propanediol | 20 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 16 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | 12 |
| Metronidazole | Metronidazole | 18 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | 11 |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Eliquis | Apixaban | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 14 |
| Ozempic | Semaglutide | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | 12 |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Tretinoin | Tretinoin | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,185.51 · 53 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, COLLAGENASE SANTYL, CREON, Cologuard Collection Kit, EVENITY, FARXIGA, ImmunoCAP, JARDIANCE, LINZESS, Leqembi, OTEZLA, OZOBAX, PROLIA, QULIPTA, REPATHA, REXULTI, REZDIFFRA, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, XIFAXAN, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error